Breast Cancer - Genome Study Links DNA Changes To The Risks Of Breast Cancer Subtypes
Can't see this email? View it online
   
  Breast Cancer  
  The latest breast cancer news from News Medical  
 Enhancing Breast Cancer Therapy through Killing ‘Sleeper Cells’Enhancing Breast Cancer Therapy through Killing ‘Sleeper Cells’
 
AZoLifeSciences speaks to Dr. James Whittle and Professor Geoff Lindeman about their research in enhancing breast cancer therapy through killing sleeper cells.
 
   Genome Study Links DNA Changes To The Risks Of Breast Cancer SubtypesGenome Study Links DNA Changes To The Risks Of Breast Cancer Subtypes
 
Genetic studies covering 266,000 women have revealed 32 new sites on the genome where variations in DNA appear to alter the risks of getting breast cancer.
 
   Honeybee venom rapidly destroys aggressive breast cancer cellsHoneybee venom rapidly destroys aggressive breast cancer cells
 
Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.
 
 Triple-negative breast cancer's ecosystem reveals potential therapeutic targets
 
Triple-negative breast cancer's ecosystem reveals potential therapeutic targetsResearchers from the Garvan Institute of Medical Research have uncovered four new subtypes of cells within triple-negative breast cancer, which contain promising new therapeutic targets for the aggressive disease.
 
 
 Researchers Find New Breast Cancer Gene In Young People
 
Researchers Find New Breast Cancer Gene In Young PeopleOver the years, our knowledge of diseases has improved, and several hereditary gene variants have been found that may predispose to the development of cancer.
 
 
 Surgical delays did not impact overall survival in patients with early stage breast cancer
 
Surgical delays did not impact overall survival in patients with early stage breast cancerBeginning in March, as COVID-19 cases surged in various states in the U.S., the COVID-19 Pandemic Breast Cancer Consortium released recommendations that operations for ductal carcinoma in situ (DCIS) be deferred due to the pandemic.
 
 
 Novel biomarkers linked to improved outcomes with immunotherapy in metastatic breast cancer
 
Novel biomarkers linked to improved outcomes with immunotherapy in metastatic breast cancerTwo novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.